Aelis Farma

Executive Summary

Aelis Farma is a French biotech pioneering Signaling Specific inhibitors (SSi) of the CB1 cannabinoid receptor, a novel approach to treat brain disorders while avoiding the side effects of full receptor blockade. Founded in 2013 and based in Bordeaux, the company is advancing two lead programs: AEF0117 for cannabis use disorder (CUD) and AEF0217 for cognitive deficits in Down syndrome (DS). Both have demonstrated promising preclinical and early clinical data. AEF0117 has completed Phase 1 and is in Phase 2 for CUD, with the potential to become the first pharmacotherapy for this indication. AEF0217 is in Phase 1/2 for DS cognitive impairment, addressing a high unmet need. The company's platform could also be extended to other CNS conditions. While still private and without approved products, Aelis Farma's SSi technology represents a unique and potentially safer therapeutic class. Key upcoming milestones include Phase 2 readouts for both programs, which will determine the path forward. The company is well-positioned within the CNS space, though execution risk remains typical for early-stage biotechs.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data for AEF0117 in cannabis use disorder60% success
• Q1 2027Phase 1/2 interim data for AEF0217 in Down syndrome cognitive deficits50% success